Active, not recruitingPHASE1, PHASE2NCT02610582
Safety and Efficacy of rAAV.hCNGA3 Gene Therapy in Patients With CNGA3-linked Achromatopsia
Studying Achromatopsia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- STZ eyetrial
- Principal Investigator
- Dominik Fischer, Prof.University Hospital Tuebingen, Center for Ophthalmology
- Intervention
- rAAV.hCNGA3(drug)
- Enrollment
- 13 enrolled
- Eligibility
- 6 years · All sexes
- Timeline
- 2015 – 2027
Study locations (1)
- University Hospital Tuebingen, Center for Ophthalmology, Tübingen, Germany
Collaborators
University Hospital Tuebingen · Ludwig-Maximilians - University of Munich
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02610582 on ClinicalTrials.govOther trials for Achromatopsia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07085533Natural History Study of Inherited Retinal DiseasesZhongmou Therapeutics
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT02935517Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial)Beacon Therapeutics
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT02599922Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial)Beacon Therapeutics